United Therapeutics Corp

詳細情報 United Therapeutics Corp 企業名

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.

United Therapeutics Corpの企業情報



企業コードUTHR

会社名United Therapeutics Corp

上場日Jun 17, 1999

最高経営責任者「CEO」Dr. Martine A. Rothblatt

従業員数1305

証券種類Ordinary Share

決算期末Jun 17

本社所在地1000 Spring St

都市SILVER SPRING

証券取引所NASDAQ Global Select Consolidated

国United States of America

郵便番号20910

電話番号13016089292

ウェブサイトhttps://www.unither.com/

企業コードUTHR

上場日Jun 17, 1999

最高経営責任者「CEO」Dr. Martine A. Rothblatt

United Therapeutics Corpの経営陣



会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Martine A. Rothblatt

Chairman of the Board, Chief Executive Officer

666.42K

--

Mr. Paul A. Mahon, J.D.

Executive Vice President, General Counsel, Corporate Secretary

36.78K

--

Mr. Richard A. Giltner

Independent Director

20.57K

+6.14%

Prof. Nilda Mesa, J.D.

Independent Director

5.47K

+12.08%

The Hon. Dr. Louis W. Sullivan, M.D.

Independent Director

3.20K

--

Mr. Michael Benkowitz

President, Chief Operating Officer

2.65K

+2.76%

Mr. Christopher Patusky, J.D.

Lead Independent Vice Chairman of the Board

2.59K

+29.50%

Ms. Jan Malcolm

Director

520.00

-57.38%

Gov. Thomas G. (Tommy) Thompson, J.D.

Independent Director

--

Mr. Christopher A. Causey

Independent Director

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Martine A. Rothblatt

Chairman of the Board, Chief Executive Officer

666.42K

--

Mr. Paul A. Mahon, J.D.

Executive Vice President, General Counsel, Corporate Secretary

36.78K

--

Mr. Richard A. Giltner

Independent Director

20.57K

+6.14%

Prof. Nilda Mesa, J.D.

Independent Director

5.47K

+12.08%

The Hon. Dr. Louis W. Sullivan, M.D.

Independent Director

3.20K

--

Mr. Michael Benkowitz

President, Chief Operating Officer

2.65K

+2.76%

収益内訳

通貨: USD更新時刻: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

事業別USD

会社名

収益

比率

Tyvaso DPI

315.20M

39.47%

Nebulized Tyvaso

168.30M

21.07%

Remodulin

155.70M

19.50%

Orenitram

123.90M

15.51%

Unituxin

61.40M

7.69%

他の

-25.90M

-3.24%

地域別USD

会社名

収益

比率

United States

798.60M

100.00%

Rest of World

38.80M

4.86%

事業別

地域別

事業別USD

会社名

収益

比率

Tyvaso DPI

315.20M

39.47%

Nebulized Tyvaso

168.30M

21.07%

Remodulin

155.70M

19.50%

Orenitram

123.90M

15.51%

Unituxin

61.40M

7.69%

他の

-25.90M

-3.24%

株主

更新時刻: Fri, Aug 15

株主統計

種類

株主統計

比率

The Vanguard Group, Inc.

9.79%

BlackRock Institutional Trust Company, N.A.

9.59%

Avoro Capital Advisors LLC

5.24%

State Street Global Advisors (US)

4.79%

Renaissance Technologies LLC

4.69%

他の

65.89%

株主統計

比率

The Vanguard Group, Inc.

9.79%

BlackRock Institutional Trust Company, N.A.

9.59%

Avoro Capital Advisors LLC

5.24%

State Street Global Advisors (US)

4.79%

Renaissance Technologies LLC

4.69%

他の

65.89%

種類

株主統計

比率

Investment Advisor

42.73%

Investment Advisor/Hedge Fund

37.74%

Hedge Fund

9.19%

Pension Fund

4.79%

Individual Investor

1.75%

Research Firm

1.73%

Bank and Trust

1.44%

Sovereign Wealth Fund

1.25%

Venture Capital

0.46%

機関投資家保有株



更新時刻: Wed, Oct 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q3

1330

44.91M

99.30%

-3.12M

2025Q2

1338

46.42M

102.62%

-2.51M

2025Q1

1369

46.67M

103.49%

-1.81M

2024Q4

1344

46.07M

102.60%

-3.00M

2024Q3

1278

45.38M

101.97%

-7.63M

2024Q2

1219

48.02M

108.26%

-2.92M

2024Q1

1151

47.12M

106.59%

-2.41M

2023Q4

1127

46.52M

99.01%

-2.26M

2023Q3

1094

46.35M

98.80%

-3.96M

2023Q2

1068

46.82M

99.96%

-3.45M

詳細を見る

株主動向



会社名

保有株式数

比率

変動額

変動率

日付

The Vanguard Group, Inc.

4.43M

9.79%

-8.97K

-0.20%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

4.34M

9.59%

-138.61K

-3.10%

Jun 30, 2025

Avoro Capital Advisors LLC

2.37M

5.24%

-305.00K

-11.40%

Jun 30, 2025

State Street Global Advisors (US)

2.17M

4.79%

-63.20K

-2.83%

Jun 30, 2025

Renaissance Technologies LLC

2.12M

4.69%

+12.10K

+0.57%

Jun 30, 2025

Wellington Management Company, LLP

1.44M

3.19%

-583.48K

-28.79%

Jun 30, 2025

AQR Capital Management, LLC

1.27M

2.82%

+364.71K

+40.15%

Jun 30, 2025

Geode Capital Management, L.L.C.

1.20M

2.65%

-23.63K

-1.93%

Jun 30, 2025

LSV Asset Management

864.62K

1.91%

-37.70K

-4.18%

Jun 30, 2025

Invesco Capital Management LLC

821.69K

1.82%

+445.52K

+118.44%

Jun 30, 2025

詳細を見る

配当金



過去5年間の配当金総支払額は 0.00 米ドルである。

日付

配当金

権利確定日

支払日

配当落ち日

データなし

株式分割



日付

種類

比率

データなし

日付

種類

比率

データなし

詳細情報 United Therapeutics Corp 企業名

United Therapeutics Corpの企業情報

United Therapeutics Corpの経営陣

収益内訳

株主

機関投資家保有株

株主動向

関連ETF

配当金

株式分割